U.S. Food Allergy Diagnosis and Treatment Market Size, Share & Forecast 2026–2032

ID: MR-11560 | Published: November 2026
Download PDF Sample

Report Highlights

  • ✓Country: United States
  • ✓Market: Food Allergy Diagnosis and Treatment Market
  • ✓Market Size 2024: USD 2.1 billion
  • ✓Market Size 2032: USD 4.2 billion
  • ✓CAGR: 9.0%
  • ✓Base Year: 2025
  • ✓Forecast Period: 2026–2032
Market Growth Chart
Want Detailed Insights - Download Sample
Analyst Findings and Recommendations
FINDING 01
Epinephrine Supply Concentrated Overseas: Epinephrine auto-injector finished doses depend on a narrow chain of overseas active ingredient suppliers, principally in India and China. A single FDA warning letter at one Asian plant can interrupt pharmacy shelves nationwide within weeks.
FINDING 02
Oral Immunotherapy Losing Ground: Oral immunotherapy is not the default winner in peanut treatment. Palforzia's daily dosing burden and Xolair's February 2024 food allergy approval from Genentech are shifting momentum toward injectables. DBV's epicutaneous patch will pressure pediatric oral immunotherapy volumes.
ANALYST RECOMMENDATION

Analyst Recommendation — Secure Dual-Sourced Epinephrine: Hospital and distributor buyers should qualify a second epinephrine auto-injector source by end-2026, pairing Viatris supply with an authorized generic from Amneal or Teva. Dual sourcing removes single-plant exposure to FDA import alerts and tariff risk on Asian-origin active ingredients.

The United States' Role in the Global Food Allergy Care Supply Chain

The United States is the largest end-market and innovation hub for food allergy care, yet it is a net importer of finished generic epinephrine and most active pharmaceutical ingredients. Domestic production centers on biologics and oral immunotherapy, including Genentech's Xolair manufacturing network and Nestlé Health Science's Palforzia supply chain, which draws peanut flour largely from growers in Georgia, Alabama, and Texas. Diagnostic reagents flow in both directions, with Thermo Fisher Scientific's ImmunoCAP assays manufactured partly in Europe and distributed through U.S. laboratories.

Trade exposure runs through import dependency on Asian active ingredients and European biologic inputs. The United States imports the majority of epinephrine active ingredient from India and China, while exporting branded immunotherapy and specialty diagnostic products to Canada, Japan, and Western Europe. Value-add remains concentrated in U.S. formulation, sterile fill-finish, packaging, and FDA-regulated distribution, which captures pricing power even when raw inputs originate abroad.

Growth Drivers for Food Allergy Diagnosis and Treatment in the United States

Biologic approvals are expanding domestic production capacity. Genentech's February 2024 Xolair approval for food allergy in patients aged one and older created new demand for omalizumab fill-finish capacity within Roche's biologics network. Manufacturers are responding by expanding sterile injectable capacity inside the United States, which reduces reliance on overseas fill-finish sites and shortens replenishment lead times for pharmacies.

Diagnostic volume growth is the second driver. Rising pediatric prevalence and wider adoption of component-resolved diagnostics in hospital laboratories are increasing reagent throughput on Thermo Fisher Scientific and Siemens Healthineers platforms. The third driver is authorized generic expansion for epinephrine auto-injectors, which lowers unit cost and broadens volume through retail and school-based channels.

Supply Chain Risks and Trade Barriers in U.S. Food Allergy Care

Active ingredient dependence is the most acute risk. Epinephrine supply relies heavily on Indian and Chinese manufacturers, and pending Section 232 pharmaceutical investigations and tariff threats directly raise landed cost for generic auto-injectors. A single FDA import alert on one supplier can remove multiple generic brands from pharmacy shelves simultaneously, as recurring auto-injector shortages since 2016 have demonstrated.

Biologic and oral immunotherapy supply chains carry cold-chain and allergen-control risk. Palforzia requires strict allergen segregation and lot-to-lot dose consistency, while omalizumab depends on controlled cold-chain distribution through specialty pharmacies. Euro-denominated biologic inputs from European partners create currency exposure, and tariff-driven increases in cell culture media components add further cost pressure on domestic manufacturers.

Trade and Investment Opportunities in U.S. Food Allergy Care

Domestic epinephrine API sourcing represents the highest-value investment gap. Contract manufacturers in New Jersey, North Carolina, and Pennsylvania with sterile fill-finish capability can capture reshoring incentives by qualifying non-Chinese active ingredient sources. Investors should prioritize generic auto-injector capacity expansion, where Amneal and Teva currently depend on overseas inputs for much of their volume.

Export opportunities lie in branded oral immunotherapy and diagnostic reagents shipped to Canada, the United Kingdom, and Australia, where food allergy reimbursement is expanding. Logistics hubs at Memphis and Louisville, home to major FedEx and UPS air cargo operations, can support time-sensitive cold-chain shipments of biologics and diagnostic kits. Peanut allergen extract production in Georgia offers vertical integration with domestic peanut supply.

Market at a Glance

MetricValue
Market Size 2024USD 2.1 billion
Market Size 2032USD 4.2 billion
Growth Rate (CAGR)9.0%
Most Critical Decision FactorSecure non-Chinese epinephrine active ingredient sourcing
Largest RegionNortheast United States
Competitive StructureConcentrated branded leaders with a competitive generic epinephrine tier

Leading Market Participants

  • Nestlé Health Science
  • Genentech
  • DBV Technologies
  • Viatris
  • Teva Pharmaceutical Industries
  • kaleo
  • Thermo Fisher Scientific
  • Siemens Healthineers
  • ALK-Abelló
  • Amneal Pharmaceuticals

Regulatory and Trade Policy Environment for Food Allergy Care

FDA oversight governs food allergy therapeutics through Biologics License Application and New Drug Application pathways, with Palforzia approved in January 2020 under a Risk Evaluation and Mitigation Strategy. Import compliance is enforced through FDA foreign facility inspections and CBP tariff classification. The trade framework includes USMCA for North American inputs and Section 301 tariffs on Chinese goods that cover certain pharmaceutical intermediates.

Investment policy shapes both pricing and reshoring. The Inflation Reduction Act's Medicare drug price negotiation provisions affect high-cost biologics, while federal and state incentives support domestic pharmaceutical manufacturing. State school epinephrine access laws sustain auto-injector demand, and pending Section 232 tariffs on branded and generic pharmaceuticals would reprice imports, making FDA inspection readiness a direct trade cost factor.

Food Allergy Care Supply Chain Outlook to 2032

By 2032, domestic production will shift toward biologics and finished auto-injector assembly, with active ingredient sourcing diversifying toward Europe, Japan, and South Korea. Oral immunotherapy and epicutaneous patch platforms will reduce reliance on imported allergen inputs as standardized extracts scale within U.S. facilities. Distribution will concentrate further in specialty pharmacies handling cold-chain biologics.

Technology changes will alter comparative advantage. Monoclonal antibody and recombinant platforms make U.S. biologics manufacturing the decisive advantage, while point-of-care IgE diagnostics will reduce laboratory reagent throughput. Export flows will tilt toward finished branded products and away from bulk allergen raw materials, strengthening the United States' value-added position in the global food allergy supply chain.

Frequently Asked Questions

Most epinephrine active ingredient is sourced from manufacturers in India and China, which exposes finished products to import alerts and tariff changes. Dual sourcing across branded and authorized generic suppliers is the most effective mitigation.
Biologic drug substances and fill-finish inputs move between the United States, Germany, and Ireland, while finished branded products are exported to Canada and Japan. Cold-chain integrity across these routes determines delivery reliability.
Diagnostic kits and reagents depend on air cargo capacity and temperature-controlled ground transport between regional distribution centers and hospital laboratories. Memphis and Louisville provide key air cargo hubs that reduce transit risk.
Section 232 actions on pharmaceuticals and their inputs would raise import costs for generic epinephrine and some specialty ingredients. Manufacturers with domestic fill-finish capacity face lower exposure.
The Northeast and Mid-Atlantic lead in pharmaceutical manufacturing and logistics capacity, including New Jersey and Pennsylvania. North Carolina and Georgia add sterile manufacturing and allergen extract production capacity.

Market Segmentation

By Product Type
  • Diagnostic Tests
  • Oral Immunotherapy
  • Biologics
  • Epinephrine Auto-Injectors
  • Sublingual Immunotherapy
By Allergen
  • Peanut
  • Tree Nuts
  • Milk
  • Egg
  • Shellfish
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
  • Online Pharmacies
  • Laboratory Networks

Table of Contents

Chapter 01 Methodology and Scope
1.1 Research Methodology
1.2 Scope and Definitions
1.3 Data Sources
Chapter 02 Executive Summary
2.1 Report Highlights
2.2 Market Size and Forecast 2024-2032
Chapter 03 United States Food Allergy Diagnosis and Treatment - Market Analysis
3.1 Market Overview
3.2 Growth Drivers
3.3 Restraints
3.4 Opportunities
Chapter 04 Product Type Insights
4.1 Diagnostic Tests
4.2 Oral Immunotherapy
4.3 Biologics
4.4 Epinephrine Auto-Injectors
4.5 Others
Chapter 05 Allergen Insights
5.1 Peanut
5.2 Tree Nuts
5.3 Milk
5.4 Egg
5.5 Others
Chapter 06 Distribution Channel Insights
6.1 Hospital Pharmacies
6.2 Retail Pharmacies
6.3 Specialty Pharmacies
6.4 Online Pharmacies
6.5 Others
Chapter 07 Competitive Landscape
7.1 Market Players
7.2 Leading Market Participants
7.2.1 Nestlé Health Science
7.2.2 Genentech
7.2.3 DBV Technologies
7.2.4 Viatris
7.2.5 Teva Pharmaceutical Industries
7.2.6 kaleo
7.2.7 Thermo Fisher Scientific
7.2.8 Siemens Healthineers
7.2.9 ALK-Abelló
7.2.10 Amneal Pharmaceuticals
7.3 Regulatory Environment
7.4 Outlook

Research Framework and Methodological Approach

Information
Procurement

Information
Analysis

Market Formulation
& Validation

Overview of Our Research Process

MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.

1. Data Acquisition Strategy

Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.

Secondary Research
  • Company annual reports & SEC filings
  • Industry association publications
  • Technical journals & white papers
  • Government databases (World Bank, OECD)
  • Paid commercial databases
Primary Research
  • KOL Interviews (CEOs, Marketing Heads)
  • Surveys with industry participants
  • Distributor & supplier discussions
  • End-user feedback loops
  • Questionnaires for gap analysis

Analytical Modeling and Insight Development

After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.

2. Market Estimation Techniques

MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.

Bottom-up Approach

Country Level Market Size
Regional Market Size
Global Market Size

Aggregating granular demand data from country level to derive global figures.

Top-down Approach

Parent Market Size
Target Market Share
Segmented Market Size

Breaking down the parent industry market to identify the target serviceable market.

Supply Chain Anchored Forecasting

MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.

Supply-Side Evaluation

Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.

3. Market Engineering & Validation

Market engineering involves the triangulation of data from multiple sources to minimize errors.

01 Data Mining

Extensive gathering of raw data.

02 Analysis

Statistical regression & trend analysis.

03 Validation

Cross-verification with experts.

04 Final Output

Publication of market study.

Client-Centric Research Delivery

MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.